Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics appointed Rich Daly, a 30-year life sciences executive, to its Board of Directors effective October 14, 2026, expanding the board to eight members, seven of whom are independent. Daly was President and CEO of Catalyst Pharmaceuticals and now leads Global Rare Disease at Angelini Pharma, with prior senior roles at Takeda and AstraZeneca including launches of Farxiga and Agamree.
Key figures
- Board size after
- 8
- Daly experience years
- 30+
- Independent directors
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.